Background: Ang II (Ang II) regulates blood volume and stimulates erythropoiesis through AT1 (ATR1) and AT2 (ATR2) receptors, being found in multiple tissues, including erythrocytes. Sickle cell disease (SCD) patients presents altered Ang II (Ang II) levels.Hypothesis: Hemoglobin S polymerization, erythrocyte adhesion, deformability and eryptosis are important features of mature erythrocyte, therefore, our hypothesis is Ang II affect these parameters and, if does, which would be the in uence of AT1R and AT2R in these effects.Methods: A Polymerization Assay (PA), static adhesion, deformability and annexin V binding were performed in SCD erythrocytes samples adding Ang II, ATR1 antagonist (losartan or eprosartan), and ATR2 antagonist (PD123319).Results: Through the PA test, we observed a dose-dependent polymerization inhibition effect when comparing Ang II to control. Losartan did not affect nor the level nor the rate of Ang II inhibition, while PD123319 showed an increased level of protection against polymerization and eprosartan brought levels back to control. Ang II does not change static adhesion but was able to reduce eryptosis in the presence of PD123319. Also, ATR1 shows a positive effect increasing deformability. Conclusion: our data shows that ATR1 is important for maintenance of erythrocyte physiological function in SCD and for prolonging its life.